Home Tags GPRC5D

Tag: GPRC5D

LaNova Signs Exclusive License Agreement with AstraZeneca for Novel GPRC5D-Targeting ADC

ADC Review | Editorial Team
LaNova Medicines and AstraZeneca have entered into an exclusive license agreement with  for LM-305, a pre-clinical stage antibody-drug conjugate (ADC) targeting G protein-coupled receptor, class C, group 5, member D (GPRC5D).
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X